Department of Intensive Care Medicine, Chongqing Health Centre for Women and Children, Chongqing, China.
Department of Medicine, Harbin Medical University, Harbin, China.
Ginekol Pol. 2024;95(7):536-543. doi: 10.5603/gpl.97752. Epub 2024 Feb 9.
To investigate the effects of intravenous nicardipine as initial therapy and oral labetalol combined with nifedipine controlled-release tablet as subsequent treatment of severe peripartum hypertension.
Intravenous nicardipine was delivered as the initial treatment, after the target blood pressure (BP) had been achieved, oral labetalol was used to maintain the target BP. If oral labetalol failed to maintain the target BP, oral labetalol combined with nifedipine controlled-release tablet was used.
A total number of 131 patients were enrolled. The target BP (BP < 140/90 mmHg) was achieved in all patients within 60 minutes by intravenous nicardipine. After receiving labetalol orally, the target BP was maintained in nine patients. However, in 104 patients, we had to combine oral labetalol and nifedipine controlled-release tablet due to re-elevation of their systolic BP to 140-159 mmHg. In 18 patients, we restarted intravenous nicardipine because their systolic BP re-elevated above 160 mm Hg. Among the 104 patients who received oral labetalol and nifedipine controlled-release tablet, the target BP was achieved and maintained in 96 patients, and eight patients had to restart nicardipine. Of the total number of 26 patients in whom intravenous nicardipine was resumed, the target BP was successfully maintained in 22 patients with oral labetalol combined with nifedipine controlled-release tablet.
Intravenous nicardipine rapidly and safely lowered severe peripartum hypertension. As subsequent therapy, oral labetalol combined with nifedipine controlled-release tablet protocol may be applied to effectively maintain a target BP.
探讨静脉用尼卡地平作为初始治疗,口服拉贝洛尔联合硝苯地平控释片作为重度围生期高血压后续治疗的效果。
静脉给予尼卡地平作为初始治疗,达到目标血压(BP)后,使用口服拉贝洛尔维持目标 BP。如果口服拉贝洛尔不能维持目标 BP,则使用口服拉贝洛尔联合硝苯地平控释片。
共纳入 131 例患者。所有患者在 60 分钟内通过静脉用尼卡地平达到目标 BP(BP<140/90mmHg)。口服拉贝洛尔后,9 例患者维持目标 BP。然而,在 104 例患者中,由于收缩压再次升高至 140-159mmHg,我们不得不联合口服拉贝洛尔和硝苯地平控释片。在 18 例患者中,由于收缩压再次升高至 160mmHg 以上,我们重新开始静脉用尼卡地平。在接受口服拉贝洛尔和硝苯地平控释片的 104 例患者中,96 例患者达到并维持了目标 BP,8 例患者需要重新开始用尼卡地平。在重新开始静脉用尼卡地平的 26 例患者中,22 例患者联合口服拉贝洛尔和硝苯地平控释片成功维持了目标 BP。
静脉用尼卡地平可快速、安全地降低重度围生期高血压。作为后续治疗,口服拉贝洛尔联合硝苯地平控释片方案可能有效维持目标 BP。